Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cemacabtagene ansegedleucel - Allogene Therapeutics

Next Previous
Drug Profile

Cemacabtagene ansegedleucel - Allogene Therapeutics

Alternative Names: ALLO-501.1; ALLO-501A; cema-cel - Allogene Therapeutics

Latest Information Update: 24 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Developer Allogene Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Chronic lymphocytic leukaemia

Most Recent Events

  • 20 Jun 2024 Allogene Therapeutics plans to submit a Biologics License Application (BLA) for cemacabtagene ansegedleucel
  • 18 Jun 2024 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy) in Canada (Parenteral) (NCT06500273)
  • 18 Jun 2024 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy) (Parenteral) in USA (Allogene Therapeutics pipeline, January 2024) (NCT06500273)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top